All Oncology News

Toni Choueiri, MD, details the PFS outcomes and safety profiles for tivozanib plus nivolumab vs tivozanib alone in metastatic renal cell carcinoma

Sheela Rao, MBBS, MD, FRCP, discusses data from the phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab plus chemotherapy vs chemotherapy in advanced SCAC.

Nirav N. Shah, MD, MSHP, details how BTK degraders could fill an unmet need in pretreated CLL/SLL and highlights promising data seen with NX-5948.

Genetic markers for venetoclax could help personalize treatment and improve outcomes

A marketing authorization application has been submitted to the EMA seeking the approval of eflornithine for patients with high-risk neuroblastoma.

The FDA has granted priority review to sunvozertinib for advanced/metastatic NSCLC with EGFR exon 20 insertion mutations after progression on chemotherapy.

Amivantamab plus lazertinib prolonged overall survival vs osimertinib as first-line therapy in locally advanced or metastatic, EGFR-mutant NSCLC.

Flonoltinib maleate generated rapid clinical benefits, including spleen volume reduction and symptom improvement, for patients with myelofibrosis.

Lenalidomide plus luspatercept demonstrated safety, tolerability, and efficacy in patients with non-del(5q) myelodysplastic syndrome.

Armin Ghobadi, MD, discusses the safety profile of WT-7 in heavily pretreated relapsed/refractory T-ALL and LBL.

Ropeginterferon alfa-2b improved responses in patients with essential thrombocythemia with resistance or intolerance to hydroxyurea.

Tom van Meerten, MD, PhD, discusses key efficacy and safety data with brexu-cel in BTK inhibitor–naive relapsed/refractory mantle cell lymphoma.

Dasom (Caroline) Lee, MD, discusses real-world data for second-line axi-cel in relapsed/refractory large B-cell lymphoma.

A study published in Science by researchers from Dana-Farber Cancer Institute demonstrated that rare germline genetic abnormalities could increase the risk of childhood cancers.

China’s NMPA has approved zolbetuximab plus chemotherapy for CLDN18.2-positive advanced gastric or GEJ adenocarcinoma.

Tarlatamab was granted conditional marketing authorization in the United Kingdom for previously treated extensive-stage small cell lung cancer.

Imetelstat plus ruxolitinib showed early tolerability and efficacy in patients with intermediate and high-risk myelofibrosis.

Anitocabtagene autoleucel generated durable response in patients with relapsed/refractory multiple myeloma.

First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer.

Aparna Parikh, MD, discusses the first-line treatment field for patients with hepatocellular carcinoma, highlighting notable immunotherapy options.

This week’s top 5 includes a snapshot of FDA approvals from December, an exclusive roundup of critical NCCN guideline updates from 2024, and more.

BMS-986253 plus nivolumab/ipilimumab failed to improve responses or PFS in advanced melanoma after progression on or after a checkpoint inhibitor.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in December 2024.

Nearly half of oncologists use AI tools for document and communication/editing purposes in their practice, and most foresee an increase in AI integration.

Nicolas Girard, MD, compares the predictive value, mechanisms of action, and safety or efficacy profile of HER2-targeted TKIs vs ADCs in NSCLC.

Data published in Oncogene suggest that the mitochondrial unfolded protein response could be an Achilles’ heel for neuroendocrine prostate cancer.

Satri-cel improved PFS vs investigator’s choice of therapy in pretreated CLDN18.2-positive advanced gastric/GEJ cancer.

China's NMPA has approved taletrectinib adipate capsule for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC.

Through prolific biomarker research, Fabrice André, MD, PhD, has worked throughout his career to make strides in personalized breast cancer care.

Tremelimumab plus paclitaxel induced responses in metastatic urothelial cancer after progression on platinum and an immune checkpoint inhibitor.